Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Published:2018-11 Issue:11 Volume:6 Page:863-873
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Yue Dongsheng,Xu Shidong,Wang Qun,Li Xiaofei,Shen Yi,Zhao Heng,Chen Chun,Mao Weimin,Liu Wei,Liu Junfeng,Zhang Lanjun,Ma Haitao,Li Qiang,Yang Yue,Liu Yongyu,Chen Haiquan,Wang Changli

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference28 articles.

1. Adjuvant chemotherapy for surgically resected non-small cell lung cancer;Heon;J Thorac Cardiovasc Surg,2012

2. Adjuvant chemotherapy for resected non-small cell lung cancer;Wakelee;Semin Thorac Cardiovasc Surg,2008

3. Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer: a systematic review;Bradbury;Clin Lung Cancer,2017

4. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer;Burdett;Cochrane Database Syst Rev,2015

5. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J Clin Oncol,2008

Cited by 236 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic insights into Retama raetam’s anti-proliferative and pro-apoptotic effects in A549 lung cancer cells: targeting PI3K/Akt pathway and ROS production;Toxicology Research;2024-09-02

2. Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario;Current Oncology;2024-08-30

3. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China;BMJ Open;2024-08

4. A narrative review on perioperative systemic therapy in non-small cell lung cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26

5. Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small cell lung cancer (ICTAN, GASTO1002): a randomized phase 3 trial;2024-07-23